<DOC>
	<DOCNO>NCT03038178</DOCNO>
	<brief_summary>The propose study ass efficacy , safety tolerability daily dose Liposomal-Amikacin Inhalation ( LAI ) 590 mg 12 month plus standard care ( SOC ) mycobacterial multi-drug regimen accordance 2007 ATS/ IDSA guideline , treatment mycobacterium abscessus lung disease .</brief_summary>
	<brief_title>Liposomal Amikacin Inhalation ( LAI ) Treatment Mycobacterium Abscessus Lung Disease</brief_title>
	<detailed_description>This open-label study efficacy , safety tolerability daily dose Liposomal-Amikacin Inhalation ( LAI ) , addition standard multi-drug antibiotic therapy accordance 2007 ATS/ IDSA guideline , patient Mycobacterium abscessus lung disease . The multi-drug therapy determine discretion Investigator . After screen , eligible patient enter trial receive LAI 590 mg daily 12 month . If deem necessary investigator , dose may adjust minimum three time per week daily , case adverse event relate tolerability . All patient enter study subsequent study visit Months 1,2,4,6,9 , End-of-Study Month 12 , 1 3 month post study drug discontinuation . At visit ( include screen ) , review concomitant medication , review adverse event , physical exam , perform . Chest CT scan perform baseline , 6 month , 12 month , unless chest CT scan already perform within 6 month time point . The 6 minute walk test QOL-B-NTM perform baseline , 6 month , 12 month , 3 month post study drug discontinuation . All patient induct sputum collect study visit , patient self-collect expectorated sputum intervene monthly time-points study completion determine change mycobacterial smear culture status . Unscheduled visit occur need subject ' symptom worsen visit .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Mycobacterium Infections</mesh_term>
	<mesh_term>Mycobacterium Infections , Nontuberculous</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>Male female patient 12 year old Diagnosis M. abscessus , include subspecies , abscessus , bolleti , massiliense lung disease accord 2007 ATS/IDSA criterion Both newly diagnose currently treatment previously treat patient included Culture positive ( either sputum bronchoscopy ) M. abscessus time screen Willingness adhere treatment regimen , study visit , study procedure course study . Ability produce approximately 3.0 mL sputum willing undergo induction produce approximately 3.0 mL sputum culture collection Female childbearing potential agrees practice acceptable method birth control ( e.g. , abstinence , hormonal barrier method , partner sterilization , IUD ) Written informed consent assent obtain patient , parent legal guardian prior performance study relate procedure Active pulmonary tuberculosis require treatment screen Treatment inhale intravenous Amikacin within 14 day prior baseline Known hypersensitivity aminoglycosides Aspartate aminotransferase alanine aminotransferase ≥ 3 time upper limit normal total bilirubin ≥ 2 time upper limit normal ( ULN ) screen Current addiction alcohol illicit drug abuse Any condition opinion Investigator interfere ability adhere study requirement Primary immunodeficiency syndrome acquire immunodeficiency syndrome ( e.g. , HIVpositive patient regardless CD4 count ) Absolute neutrophil count ≤500/μL Screening Significant ( determine investigator ) hearing loss , vestibular dysfunction , neuromuscular weakness diagnosis myasthenia gravis , potential risk aminoglycoside toxicity outweigh potential benefit Serum creatinine &gt; 2 time ULN Screening History lung transplantation Any condition , judgment Investigator , would compromise ability subject complete study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Mycobacterium Infections , Nontuberculous</keyword>
	<keyword>Mycobacteria , Atypical</keyword>
	<keyword>Amikacin</keyword>
	<keyword>Inhalation</keyword>
</DOC>